Article in Gastroenterology & hepatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
4 authors.
Timothy M BlockDr Block and Dr Zhou are professors and project leaders at the Baruch S. Blumberg Institute in Doylestown, Pennsylvania. Mr Anbarasan was affiliated with the Baruch S. Blumberg Institute at the time of this article but is now a third-year medical student affiliated with Flushing Hospital and Medical Center in Flushing, New York. Dr Gish is a professor consultant in the Department of Medicine in the Division of Gastroenterology and Hepatology at Stanford University in Stanford, California; principal of Robert G. Gish Consultants, LLC, in San Diego, California; senior medical director at St Joseph's Hospital and Medical Center in Phoenix, Arizona; and chief medical advisor of the Hepatitis B Foundation in Doylestown, Pennsylvania.
Tianlun ZhouDr Block and Dr Zhou are professors and project leaders at the Baruch S. Blumberg Institute in Doylestown, Pennsylvania. Mr Anbarasan was affiliated with the Baruch S. Blumberg Institute at the time of this article but is now a third-year medical student affiliated with Flushing Hospital and Medical Center in Flushing, New York. Dr Gish is a professor consultant in the Department of Medicine in the Division of Gastroenterology and Hepatology at Stanford University in Stanford, California; principal of Robert G. Gish Consultants, LLC, in San Diego, California; senior medical director at St Joseph's Hospital and Medical Center in Phoenix, Arizona; and chief medical advisor of the Hepatitis B Foundation in Doylestown, Pennsylvania.
Nikhil AnbarasanDr Block and Dr Zhou are professors and project leaders at the Baruch S. Blumberg Institute in Doylestown, Pennsylvania. Mr Anbarasan was affiliated with the Baruch S. Blumberg Institute at the time of this article but is now a third-year medical student affiliated with Flushing Hospital and Medical Center in Flushing, New York. Dr Gish is a professor consultant in the Department of Medicine in the Division of Gastroenterology and Hepatology at Stanford University in Stanford, California; principal of Robert G. Gish Consultants, LLC, in San Diego, California; senior medical director at St Joseph's Hospital and Medical Center in Phoenix, Arizona; and chief medical advisor of the Hepatitis B Foundation in Doylestown, Pennsylvania.
Robert GishDr Block and Dr Zhou are professors and project leaders at the Baruch S. Blumberg Institute in Doylestown, Pennsylvania. Mr Anbarasan was affiliated with the Baruch S. Blumberg Institute at the time of this article but is now a third-year medical student affiliated with Flushing Hospital and Medical Center in Flushing, New York. Dr Gish is a professor consultant in the Department of Medicine in the Division of Gastroenterology and Hepatology at Stanford University in Stanford, California; principal of Robert G. Gish Consultants, LLC, in San Diego, California; senior medical director at St Joseph's Hospital and Medical Center in Phoenix, Arizona; and chief medical advisor of the Hepatitis B Foundation in Doylestown, Pennsylvania.
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Is a cure for chronic hepatitis B virus (HBV) infection possible? Hepatitis C virus infection is now routinely cured medically. There is a growing expectation that new drugs for the management of chronic HBV infection should provide substantial benefit over and above that of current chronic HBV medications, if not be curative. Although the definition of medically induced cure for chronic HBV infection varies, most include sustained off-drug absence of viremia and negativity for other virologic markers. There are currently more than 29 drugs in the pipeline being tested for the management of chronic HBV infection. This article discusses the potential drugs with respect to their possible contributions to achieving medically induced cure.
Indexed as
antiviralsendpointsexperimental therapyHepatitis B virustherapy
Identifiers
PMID28035197
PMCPMC5193088
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Evolving New Strategies for the Medical Management of Chronic Hepatitis B Virus Infection. · full record | OpenQuestion